Selecting the right target and lead indication is one of the most critical choices in a biotech’s trajectory, yet it is rarely straightforward.
For platform organizations, the challenge grows as the search spans millions of potential combinations, far beyond what traditional reviews or internal capacity can manage effectively.
In this white paper, Scitaris co-founder Jonathan Vonnemann, PhD and senior consultant Wignand Mühlhäuser, PhD discuss how structured search and prioritization frameworks help preclinical teams:
